Logo image of ALHC

ALIGNMENT HEALTHCARE INC (ALHC) Stock Fundamental Analysis

NASDAQ:ALHC - Nasdaq - US01625V1044 - Common Stock - Currency: USD

14.48  -0.01 (-0.07%)

After market: 14.55 +0.07 (+0.48%)

Fundamental Rating

3

Overall ALHC gets a fundamental rating of 3 out of 10. We evaluated ALHC against 102 industry peers in the Health Care Providers & Services industry. ALHC has a bad profitability rating. Also its financial health evaluation is rather negative. ALHC is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALHC had negative earnings in the past year.
In the past year ALHC had a positive cash flow from operations.
ALHC had negative earnings in each of the past 5 years.
In multiple years ALHC reported negative operating cash flow during the last 5 years.
ALHC Yearly Net Income VS EBIT VS OCF VS FCFALHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -10.12%, ALHC is doing worse than 75.49% of the companies in the same industry.
Looking at the Return On Equity, with a value of -83.81%, ALHC is doing worse than 74.51% of the companies in the same industry.
Industry RankSector Rank
ROA -10.12%
ROE -83.81%
ROIC N/A
ROA(3y)-21.65%
ROA(5y)-20.54%
ROE(3y)-95.11%
ROE(5y)-84.8%
ROIC(3y)N/A
ROIC(5y)N/A
ALHC Yearly ROA, ROE, ROICALHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

Looking at the Gross Margin, with a value of 11.57%, ALHC is doing worse than 73.53% of the companies in the same industry.
In the last couple of years the Gross Margin of ALHC has declined.
ALHC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 11.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y-2.77%
ALHC Yearly Profit, Operating, Gross MarginsALHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10

More info and screens

3

2. Health

2.1 Basic Checks

ALHC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALHC has been increased compared to 1 year ago.
ALHC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ALHC is higher compared to a year ago.
ALHC Yearly Shares OutstandingALHC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
ALHC Yearly Total Debt VS Total AssetsALHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

ALHC has an Altman-Z score of 4.13. This indicates that ALHC is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ALHC (4.13) is better than 78.43% of its industry peers.
The Debt to FCF ratio of ALHC is 16.87, which is on the high side as it means it would take ALHC, 16.87 years of fcf income to pay off all of its debts.
ALHC has a Debt to FCF ratio (16.87) which is in line with its industry peers.
ALHC has a Debt/Equity ratio of 2.98. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.98, ALHC is doing worse than 78.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.98
Debt/FCF 16.87
Altman-Z 4.13
ROIC/WACCN/A
WACC9.03%
ALHC Yearly LT Debt VS Equity VS FCFALHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.69 indicates that ALHC should not have too much problems paying its short term obligations.
With a Current ratio value of 1.69, ALHC perfoms like the industry average, outperforming 57.84% of the companies in the same industry.
ALHC has a Quick Ratio of 1.69. This is a normal value and indicates that ALHC is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.69, ALHC is in the better half of the industry, outperforming 61.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 1.69
ALHC Yearly Current Assets VS Current LiabilitesALHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.37% over the past year.
The Revenue has grown by 49.12% in the past year. This is a very strong growth!
The Revenue has been growing by 28.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)43.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)49.12%
Revenue growth 3Y32.29%
Revenue growth 5Y28.99%
Sales Q2Q%47.46%

3.2 Future

Based on estimates for the next years, ALHC will show a very strong growth in Earnings Per Share. The EPS will grow by 27.85% on average per year.
Based on estimates for the next years, ALHC will show a very strong growth in Revenue. The Revenue will grow by 26.41% on average per year.
EPS Next Y47.29%
EPS Next 2Y36.98%
EPS Next 3Y30.38%
EPS Next 5Y27.85%
Revenue Next Year41.47%
Revenue Next 2Y33.39%
Revenue Next 3Y30.1%
Revenue Next 5Y26.41%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALHC Yearly Revenue VS EstimatesALHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2031 2B 4B 6B 8B 10B
ALHC Yearly EPS VS EstimatesALHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALHC. In the last year negative earnings were reported.
Also next year ALHC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALHC Price Earnings VS Forward Price EarningsALHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

ALHC's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. ALHC is more expensive than 61.76% of the companies in the same industry.
Industry RankSector Rank
P/FCF 150.06
EV/EBITDA N/A
ALHC Per share dataALHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

ALHC's earnings are expected to grow with 30.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.98%
EPS Next 3Y30.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALHC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALIGNMENT HEALTHCARE INC

NASDAQ:ALHC (5/23/2025, 9:12:50 PM)

After market: 14.55 +0.07 (+0.48%)

14.48

-0.01 (-0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners60.36%
Inst Owner Change2.83%
Ins Owners4.19%
Ins Owner Change18.94%
Market Cap2.86B
Analysts81.18
Price Target18.74 (29.42%)
Short Float %8.36%
Short Ratio3.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)39.85%
Min EPS beat(2)18.53%
Max EPS beat(2)61.17%
EPS beat(4)4
Avg EPS beat(4)23.63%
Min EPS beat(4)3.21%
Max EPS beat(4)61.17%
EPS beat(8)6
Avg EPS beat(8)13.78%
EPS beat(12)9
Avg EPS beat(12)18.35%
EPS beat(16)11
Avg EPS beat(16)4.29%
Revenue beat(2)2
Avg Revenue beat(2)1.95%
Min Revenue beat(2)1.59%
Max Revenue beat(2)2.3%
Revenue beat(4)4
Avg Revenue beat(4)2.79%
Min Revenue beat(4)1.59%
Max Revenue beat(4)4.75%
Revenue beat(8)8
Avg Revenue beat(8)2.67%
Revenue beat(12)11
Avg Revenue beat(12)3.12%
Revenue beat(16)15
Avg Revenue beat(16)4.1%
PT rev (1m)5.91%
PT rev (3m)31.25%
EPS NQ rev (1m)2%
EPS NQ rev (3m)4.72%
EPS NY rev (1m)10.96%
EPS NY rev (3m)31.44%
Revenue NQ rev (1m)1.57%
Revenue NQ rev (3m)7.95%
Revenue NY rev (1m)1.07%
Revenue NY rev (3m)9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.95
P/FCF 150.06
P/OCF 49.67
P/B 26.47
P/tB 41.25
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.1
FCFY0.67%
OCF(TTM)0.29
OCFY2.01%
SpS15.19
BVpS0.55
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.12%
ROE -83.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 11.57%
FCFM 0.64%
ROA(3y)-21.65%
ROA(5y)-20.54%
ROE(3y)-95.11%
ROE(5y)-84.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y-2.77%
F-Score6
Asset Turnover3.35
Health
Industry RankSector Rank
Debt/Equity 2.98
Debt/FCF 16.87
Debt/EBITDA N/A
Cap/Depr 134.51%
Cap/Sales 1.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 1.69
Altman-Z 4.13
F-Score6
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)151.69%
Cap/Depr(5y)136.01%
Cap/Sales(3y)1.72%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y47.29%
EPS Next 2Y36.98%
EPS Next 3Y30.38%
EPS Next 5Y27.85%
Revenue 1Y (TTM)49.12%
Revenue growth 3Y32.29%
Revenue growth 5Y28.99%
Sales Q2Q%47.46%
Revenue Next Year41.47%
Revenue Next 2Y33.39%
Revenue Next 3Y30.1%
Revenue Next 5Y26.41%
EBIT growth 1Y52.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year145.3%
EBIT Next 3Y49.82%
EBIT Next 5YN/A
FCF growth 1Y-24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.33%
OCF growth 3YN/A
OCF growth 5Y30.43%